| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3296530 | Gastroenterology | 2010 | 11 Pages |
Abstract
In patients with chronic hepatitis C and moderate fibrosis, 52 weeks of treatment with farglitazar does not affect stellate cell activation or fibrosis (measured by morphometry or comparison of paired biopsy specimens).
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
John McHutchison, Zachary Goodman, Keyur Patel, Hala Makhlouf, Maribel Rodriguez-Torres, Mitchell Shiffman, Don Rockey, Petr Husa, Wan-Long Chuang, Robert Levine, Mark Jonas, Dickens Theodore, Richard Brigandi, Alison Webster, Margaret Schultz,